Ladies and gentlemen, welcome to the report on first quarter 2026 earnings conference call. I am Valentina, the call's call operator. I would like to remind you that all participants will be in listen only mode, and the conference is being recorded. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing star one on your telephone. For operator assistance, please press star zero. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Dr. Dominik Heger. Please go ahead. Thank you, Valentina. I would like to welcome everyone to our earnings call for the first quarter 2026. As always, I start out the call by mentioning our cautionary language that is in our safe harbor statement as well as in our presentation and in all the materials that we have distributed earlier today. For further details concerning risks and uncertainties, please refer to these documents and to our SEC filings. We will have a little bit under an hour for the call. In order to give everyone the chance to ask questions, we would limit the number of questions to two. Thank you for making this work as always. Let me now welcome Helen Giza, CEO and Chair of the Management Board, and Martin Fischer, our Chief Financial Officer. Helen, the floor is yours. Thank you, Dominik. I'd like to extend a warm welcome to everyone on the call. Thank you for your continued interest in Fresenius Medical Care. I will begin my prepared remarks on slide four. I am pleased to report that we began 2026 with continued operational and financial progress. We realized a solid organic revenue growth of 4%, reflecting positive contributions from all segments. We achieved strong operating income growth of 10% in line with our planned phasing for the year and leading to further margin expansion. This was supported by continued execution of our FME25+ saving program, which delivered EUR 50 million in sustainable savings in the quarter. On 30th of April, we successfully completed our initial share buyback program of EUR 1 billion in a significantly accelerated way. It was done in less than one year instead of within two years as originally announced. We bought back 24.8 million shares or 8.5% of share capital. At the same time, our net leverage ratio of 2.6x remains around the lower end of our target corridor. Let me now turn to key first quarter highlights across our operating segments on slide five. Beginning with Care Delivery in the U.S., same-market treatment growth declined by 37 basis points as volumes were impacted by mistreatments. We had flagged during the quarter that we experienced severe U.S. weather events in January and February. As we focus on core operational improvements with clinics closures and insurance verification, this likely had a small impact on patient inflows at the start of the year. This was further complicated by the unclear situation for many patients with their insurance coverage due to the expiry of the extended tax subsidies for ACAs. Volumes also continue to face pressure from mortality remaining above pre-pandemic levels. We are maintaining our assumption of flat U.S. same-market treatment growth in 2026, which includes the expectation for improving volumes over the course of the year. Our Care Delivery International markets delivered 1.3% same-market treatment growth. While TDAPA provided a benefit to our Care Delivery performance, Martin will address that in his remarks. What really stands out to me is the successful execution of our FME Reignite strategy and the actions we are taking to strengthen our Care Delivery business while driving profitable growth. We understand the sense of urgency as well as the pace and momentum needed to deliver growth in our underlying business. There are several proof points demonstrating progress already. While mortality levels are still above pre-pandemic level, we have seen a reduction in catheter-related bloodstream infections, with now around 90% of all eligible patients using an antimicrobial catheter lock solution. This is part of our FME Reignite strategic priority to increase patient quality and safety. We expect the progress we have made on increased usage of catheter lock solutions to begin to have a positive impact on mistreatments and mortality in the near future. The 5008X rollout and introduction of HighVolumeHDF therapy represents the biggest operational and clinical change in our company's history. With the start of the large scale launch in January, we have achieved a clear step up change in rollout speed and are well on track. We surpassed 100,000 treatments on the 5008X in the first week of April, and around 100 clinics have been converted to the new care system, with more conversions underway as we speak. In February, as part of FME25+, we announced the biggest U.S. clinic restructuring in recent history, with plans to close up to 100 clinics. Here, we are also moving at speed with 64 clinics already exited in the first quarter and the remainder expected within Q2. Finally, we have realized improvements in revenue cycle management, providing further evidence of our strategic execution. Turning to Value-Based Care, we delivered positive operating income driven by favorable savings rate, and we realized an increase in member months from future contracting growth. Leveraging data and analytics to improve quality and coordination of care is one central component of our FME Reignite strategy. We have expanded adoption of AI-driven interventions for imminent hospital admissions of ESRD patients. Where employed, these programs have shown a reduction in hospitalizations by as much as 15% and missed dialysis treatments per member per month by up to 26% for the highest risk patients. We will continue to scale this across our VBC population. I'm also proud to report that we continue to be recognized for quality leadership in the United States Government CKCC program for multiple consecutive years. We delivered over $270 million in shared savings and achieved an 88% average quality score over the first three years of the program. In the most recent publicly available data, we earned over 40% of the program's high performer pool, driven by our industry-leading quality. Care Enablement realized favorable business growth as sales of the 5008X in the U.S. ramp up. This is a tremendous opportunity to bring new innovation to the U.S. market, and we are on track with production to supply both machines and consumables according to our targets for the year. In the first quarter, we achieved positive pricing and volume development in our markets outside of China. We faced continued pressure in China, especially from volume-based procurement and stricter tender requirements. We continue to closely monitor developments in China and assess the implications on our product portfolio and strategy as part of FME Reignite. We also continue to strengthen our core Care Enablement business with further FME25+ progress in streamlining our manufacturing and supply chain. I will now hand over to Martin to walk you through the first quarter financials in more detail. Thank you, Helen, and welcome to everyone on the call also from my side. I will pick up on slide seven. In the first quarter, we achieved solid organic revenue growth of 4%, supported by growth in all three operating segments. At constant currency, revenue increased by 3%. Care Enablement revenue development continued to face headwinds from regulatory pressure in China. Divestitures negatively impacted revenue development by 50 basis points. We delivered strong operating income growth of 10% at constant currency. This increase was supported by contributions from all operating segments and is in line with our expected phasing for our 2026 outlook. Special items in the first quarter amounted to a net negative EUR 181 million, mainly reflecting costs associated with FME25+ as we accelerated our U.S. clinic closures. In line with expectations, FME25+ costs are planned to come down over the course of the year as costs related to U.S. clinic closures are first half loaded. Turning to slide eight. This chart illustrates the year-over-year improvement of the group operating income margin, highlighting a further increase of 70 basis points. With 10.1%, this is a solid start toward achieving our projected group operating income margin of 10.5%-12% for the full year. Care Delivery was the main driver of improved profitability with a small contribution from Value-Based Care. The higher intersegment elimination reflects the 5008X care system sales in the United States. Corporate costs increased by EUR 37 million. This was mainly driven by the planned cost of strategic IT platform investments, including preparation for the transition to SAP S/4HANA. FX translation effects were unfavorable this quarter and stood at EUR -34 million. The average U.S. dollar exchange rate in the first quarter was $1.17, compared to $1.16 in the fourth quarter and compared to $1.05 in the first quarter of 2025. I will now walk you briefly through the business developments in each segment, starting with Care Delivery on slide nine. Care Delivery achieved organic revenue growth of 6%, driven by both Care Delivery U.S., despite muted U.S. volumes and Care Delivery International. At constant currency, revenue increased by 5%. In the U.S., growth was driven by a positive impact from the TDAPA reimbursement regulations, as well as favorable rate and payer mix effects. Our U.S. payer mix remained strong in the quarter, with relatively low attrition in the exchange patient population. We expect that attrition to increase over the course of 2026 as grace periods expire and affordability pressures grow around higher premium and out-of-pocket costs. We continue to expect an impact of around EUR 50 million for full year 2026. The impact from divestitures as part of our portfolio optimization plan reduced revenue growth by about 80 basis points. The main driver here was the prior year divestment of our clinics in Brazil. Care Delivery realized strong operating income growth of 26%. This resulted in a margin improvement to 12.1%. Benefits from the TDAPA reimbursement regulation for phosphate binders and Citrasate solutions were, as expected, a meaningful driver of the earnings development. We continue to assume a significant headwind from the TDAPA reimbursement regulation in the second half of the year. Importantly, excluding the TDAPA benefit, the underlying business realized around 6% earnings growth on a constant currency basis. This includes favorable rate and mix effects, lower implicit price concessions thanks to our revenue cycle management initiatives and partially offsets planned strategic investments for the 5008X rollout in our U.S. clinics. Savings from the FME25+ program contributed positively. The anticipated labor costs increased as well as currency translation effects had a negative impact in the development. Turning to Value-Based Care on slide 10. Value-Based Care realized 3% revenue growth on both an organic and constant currency basis. This was driven by a higher number of member months from contract expansion and positive effects from premium rates. Prior period contract true-ups also created positive growth in the first quarter. This was partially offset by the change of risk type for a large contract, resulting in a different accounting treatment and lower revenue recognition. We expect revenue growth will turn negative throughout the year, primarily due to that change in accounting treatment. Operating income for Value-Based Care increased significantly in relative terms, and the margin was enhanced by 100 basis points. Value-Based Care was profitable for the second consecutive quarter. The increase in business growth was mainly driven by an enhanced savings rate. FME25+ program-related savings resulted from the reorganization of the team to take advantage of integration with Fresenius Medical Care and becoming more efficient while aligning staffing with our strategic priorities. Higher inflation and currency translation effects were offsetting factors. I return to Care Enablement on slide 11. Revenue in Care Enablement increased by 1% on an organic and constant currency basis. Organic revenue development reflects continued positive volumes and pricing, excluding adverse regulatory impacts in China, which include volume-based procurement and stricter tender requirements. Revenue was also supported by strong sales of the 5008X care systems in the United States. Care Enablement earnings slightly increased on a constant currency basis, leading to a 40 basis point margin improvement. Business growth was impacted by adverse regulatory impacts in China and negative currency translation effects. Positive volume and price effects outside of China contributed positively to business growth. Additional FME25+ savings from continued progress in manufacturing and supply chain initiatives supported margin expansion. Inflationary costs increased and had a negative effect. Next, I will look at the cash flow growth on slide 12. As always in the first quarter, we have a seasonality effect in invoicing, which is why the quarter typically represents a relatively low share of the full year operating cash flow. This year, while on the typical lower quarter one level, we realized a strong increase in operating cash flow by 39%. The main driver was favorable working capital management. Free cash flow increased by 94% to EUR 40 million. Total debt and lease liabilities as well as total net debt and lease liabilities were broadly stable compared to the prior year period. As part of our share buyback program, we repurchased a total of 23.3 million shares for EUR 941 million by the end of the first quarter. This represents 7.9% of share capital. On April 30th, we successfully completed our initial share buyback program of EUR 1 billion. We bought back in an accelerated way 24.8 million shares or 8.5% of share capital. With 2.6 x, our net leverage ratio continued to be around the lower end of our self-imposed target corridor of 2.5x-3 x. I will now hand back to Helen. Thanks, Martin. I will pick up with the outlook slide on slide 14. Given our strong first quarter performance and current expectations for the remainder of 2026, we are confirming our full year outlook. We continue to expect a broadly flat revenue development. For earnings, we assume operating income will remain on a consistently high level as 2025, with an upside downside range of a mid-single-digit percentage change. We clearly target to maintain our enhanced profitability. Unchanged to our assumptions, we do expect a positive earnings growth in the first half of 2026. Due to the phasing of the regulatory TDAPA effects, which should present a significant headwind in the second half of the year, we assume a negative earnings growth in the back half of 2026. As you will be asking about the impacts from the Middle East crisis, I want to say that we are closely monitoring inflationary impacts from higher oil prices, raw material costs, and other supply chain and transportation cost related topics. Far, there were no meaningful interruptions of our local operations during the first quarter, and the financial impacts are currently absorbed within our range of inflation assumptions for our 2026 outlook. We are closely monitoring this, have implemented mitigation measures, and will keep you updated. This concludes my prepared remarks, and I now hand back to Dominik to begin the Q&A session. Thank you, Helen. Thank you, Martin. Before I hand over for the Q&A, as always, I would like to remind you, please, start with two questions only, and if we have time left, we'll go a second round. With that, I hand it over to Valentina to open the Q&A, please. Thank you. We will now begin the question-and-answer session. Anyone who wishes to ask a question may press star and one on their telephone. You will hear a tone to confirm that you have entered the queue. If you wish to remove yourself from the question queue, you may press star and two. Questioners on the phone are requested to disable the loudspeaker mode while asking a question. Anyone who has a question may press star and one at this time. Back over to you, Dominik, for the first question. Thank you, Valentina. The first question comes from Graham from UBS. Graham, the floor is yours. Morning, guys. Thanks for taking the question or afternoon even. And obviously congratulations on the 5008X rollout. That's obviously a big and logistical undertaking. I was hoping you might be able to contextualize that and some of the other growth drivers you expect it to build through the year. It's just when I look at the underlying growth for Q1, if you adjust for the TDAPAs, it looks like there's quite a bit of work to do as we go through the year when we think of the kind of mid-teens implied growth in consensus for 2027. I was sort of just thinking, how do you get there? How do you get to that sort of mid-teens growth for next year when you exit that TDAPA piece? Is it more cost savings? Is there another TDAPA coming? Presumably the volume uplift won't start just yet from HV HDF, but it'd be good to get a sense as to which of those drivers are making you confident on that. Thank you. Thanks, Graham. I'll take that. You know, obviously we outlined, you know, a lot of the, you know, the drivers for Reignite and how we get to those mid-teens margins. You know, kind of the, you know, the specific building blocks clearly are, you know, ongoing FME25+, as you rightly said. The 5008X obviously is expected to ramp up not just over this year, but over those, you know, next couple of years as well. The work that we are doing and have constantly spoke to about improving inflows and outflows is quite, you know, multifactorial there. We're obviously, you know, working on improving our internal processes and even the work that we're doing on the, you know, catheter lock solutions in improving patient safety, patient quality will have a positive effect, as will HDF on treatment volumes, reduced hospitalizations, reduced mistreatments, and of course, longer mortality, or improved mortality, I should say. You know, as we think about the rev cycle management, we've got some nice contribution coming in for that. That will continue to ramp up, you know, over the course of the year. Then as you can appreciate the clinic closures, which is a big part of the one-time cost in Q1, we'll start to get those savings continuing to compound over the course of the year. You know, a lot of building blocks there, not new building blocks, but ones that we're continuing to work through. I think, you know, the other piece, as we go then specific and that maybe most of those are specific to Care Delivery, as we think about Care Enablement, obviously there's FME25+ there. I think, you know, the China piece, and I'm sure there'll be questions on that, we, you know, we've sized that for the year, knew that we'd have a bigger impact in Q1. That should also be behind us, or, you know, kind of either because the full number more heavy loaded in the first half. You know, that ongoing work on good contracting, pricing, reimbursement, and volume. I'm confident in the plans. We've clearly, you know, underscored and underpinned the initiatives across all three segments, and we're executing against that, you know, crystal clear on the aspiration to be at mid-teens margins for all segment. Well, I shouldn't say all segment, I shouldn't say VBC. Tommy will tell me. But definitely for Care Delivery and Care Enablement. And I think that's why, you know, it's important we understand the TDAPA piece. We understand the cliff that will happen. We are really focused on that underlying improvement and personally really encouraged by that 6% underlying improvement in Care Delivery in the quarter. Recognize a lot of moving parts, a lot of good initiatives, and I think we're really starting to see them come through. The clear building blocks of how we get there. Maybe just a quick follow-up on [Defen]. Are you guys seeing the benefits fairly quickly? It seems like something you might see a little bit of a tailwind relatively quickly from- For which, Graham? Did you say HDF? For DefenCath. DefenCath? [audio distortion] catheter, products. Yes, for sure. With having more than 90% of our patients on that, we are really starting to see, you know, a real improvement and reduction in bloodstream-related infections. Really encouraged by that work. Of course, we know, you know, with the DefenCath, you know, that's a TDAPA period, the underlying catheter lock solution is really good for, you know, the patient safety, patient quality. Outside the financial impact of that, clear improvement that should be expected to translate into reduced hospitalizations and reduced mistreatments with, you know, with the patients over time. Awesome. Thanks a lot, guys. Thank you. The next question comes from Hassan from Barclays. Hassan, the floor is yours. Good afternoon. Thank you for taking my questions. Firstly, on the TDAPA benefit in the quarter, can you talk to the split of the EUR 80 million, be it phosphate binders versus catheter lock in the quarter, and how you see Q2 and H2, if this is consistent with the expectations that you set out in February. Secondly, on same-market treatment growth, if you could help unpack some of the underlying dynamics and if possible, how much of a headwind you think you may have seen from weather in Q1. With no second flu spike, do you expect growth to swing quite meaningfully in the second quarter, all else equal and perhaps into positive territory? Is there something else in Q1 that should constrain that improvement that you might be seeing, be it inflow or mortality? Thank you. Thanks, Hassan. Martin, do you want to unpack the financials on TDAPA? I suspect many have the same question. Yeah. Why don't you walk through that and I'll take the same-market treatment growth question. Yep, got it. The contribution of TDAPA for the first quarter, as you said, Hassan, was about EUR 80 million on constant currency basis. We have also told you and shared with you that the catheter lock solution contribution from 25 to 26 would be in equal size, meaning EUR 90 million for the first half year. We saw about half of that come through in the first quarter as well. The remainder between that and the EUR 80 million is a binder contribution. Overall, our TDAPA contribution has developed as expected. We have, as a reminder, positive contributions for the first half of 2026, and we expect negative headwinds in the second half. That's why we also have, when we talk about operating income improvement for the first half, a positive growth and for the second half, a negative growth expectation year-over-year. Thanks, Martin. Hassan, I'll take the same-market treatment growth 'cause I expect people have a similar question here too. Look, it's, we all know we're in small numbers on small numbers here. We know that we had weather in January and February that did result in mistreatments. Flu was similar in Q1 2026 to what it was in Q1 2025. You know, we are, you know, kind of unpacking. We did see slightly lower referrals in the first part of the year. Obviously, you know, we know we've got a lot of clinic closures and restructuring underway. We also know that, you know, the ACA piece did cause a lot of uncertainty on patients, and we're also refining our own patient insurance verification processes. Look, our guide is unchanged. We do still expect to be flat full year. I haven't even seen April numbers yet, so not in a position clearly to give insights into Q2. We do expect to continue to improve over the course of the year. Obviously, the other impacts that I spoke to, you know, on Graham's question about things like bloodstream-related infections, HDF, and the ongoing work we're doing across the operation on improving inflows and outflows is important. I think the other thing worth noting is mortality is still elevated. That, you know, that is something, you know, that we, you know, continue to try and impact through some of these other measures. All in all, I would say it's small numbers. Obviously, I know we're all looking for that to turn positive. Because of the small number, it's not really impacting our why, as we have, kind of maybe consistently said. Really feeling good about the work that's underway. Obviously, we'll continue to see more as Q2 develops. Perfect. Thank you. Of course. Thank you. The next question comes from Veronika from Citi. Veronika, floor is yours. Okay. Veronika, if you're not on mute- Sorry. Okay. Can you guys hear me? I'll put you on mute. Yes. Yes. Sorry, I can't press the, I can't press the unmute button. Good afternoon, thanks for taking my questions. Two for me, please. The first one is sort of a slightly bigger question, I guess, Helen. You know, I know we're early in the HDF rollout, just curious to get some feedback from you both in terms of operationally how that rollout is going on in your own clinics, how you're feeling about some of the early signs of mortality benefits that you're seeing, if any. I know it's very early, to the extent that you can talk about it. I guess some of the training costs that you've budgeted for in a year or how you're tracking against those. I have a bigger picture follow-up question, but maybe we can get this out of the way first. Sure. As you know, it's my favorite topic, we can spend the rest of the call talking about HDF if we like. All kidding aside, really, really happy and excited about how it's going and the progress we're making. We are accelerating at speed now. I mean, if you look at our website, you'll see clinics coming soon. You know, we're already past the 100 we were at by the end of the quarter. Training is going well. You know, those costs are incurred and being incurred as we forecast. That's all fine. The adoption in the clinics is really, really positive. As you know, it's easier to train. The staff are loving it. It's less noisy, less disruptive with, you know, alarms and beeps and things going off. More importantly, the feedback from our patients is terrific. You know, we're clearly seeing the immediate benefits of patients feeling better on these treatments, feeling less tired, et cetera. Now, you know, I've been pretty consistent on this, and it kind of maybe just a caution. Like, obviously, we are tracking a data set from patient one. We've got 100,000 treatments here, and over 100 clinics. We are starting to get that data set into a, you know, a form that we can kinda start to tease out some KPIs and report out on it. Obviously, we want to get a little bit more, you know, of the data set under our belt. We had kinda said, we'll, you know, once we're maybe through half 1 here, start to give more color on those KPIs. Everything so far is, you know, in real-world evidence, is supporting what we had seen through the studies. Yeah, obviously, it's big. It's the biggest thing we've ever done, but the level of excitement and engagement and adoption by our teams, our physicians, and our patients is terrific. Very happy with how that's going. That's super helpful, Helen. I think it maybe just to sort of lead it into my second question. I guess, you know, we're all anxiously awaiting that return of the same-market to a positive territory. I know you can't predict when that happens, I guess just fundamentally, if we're here again, you know, in 12 - 18 months' time, and we haven't seen any progress on same-market treatment growth, how will you think differently about operating the business or running the business? You know, we're seeing more clinic closures this year. Just curious, kind of high-level thoughts. I know that's not your working assumption, to the extent that we're there in, you know, in 2027, what should we be expecting from you in response to that? Thanks so much. First of all, my expectation is 12-18 months, we wouldn't be at, you know, negative same-market treatment growth. I do expect this to continue to improve. I feel really good about the work the FKC and CG team are doing in addressing a lot of these, you know, operational improvements and efficiencies and both addressing inflows and outflows. I think if, and it's a big if, we are in a situation where even with upgrades. You have to think about 18 months from now, Veronika, we would have, you know, technically also converted about 40% of our machines. We should also be seeing, you know, the real nice impact coming through on HDF. As we have shown this year, where we know we have underutilized capacity or we don't have profitable growth, clearly we would trim the network accordingly, that is not our working assumption. Obviously, you know, every month, every data point gives us a new insight. I think, you know, what we're seeing in the work that we're doing, both on the patient safety, patient quality initiatives, as well as HDF, you know, I think all the signs are pointing to that improving mortality, improving morbidity, improving hospitalizations. As always, we know that we would have to flex a different cost muscle if need be along the way. I think, you know, what I'm also would commend the team on is, as we were looking at this 100 that we've teed up on clinic closures, not just 64 through the first quarter, but that should be done, you know, sometime in May. We've already got, I think, close to 90 done through April. That's also a good proof point that we can move at speed, should we need to go deeper here. Got it. Thank you so much. Of course. Super. Thank you. The next question comes from Hugo from BNPP. Hugo, the floor is yours. Hi, guys. Thanks for taking my questions. I have two, please. First, on the EUR 200 million-EUR 300 million inflation headwind that's in the guide, could you maybe give us an indication of how you track against that guide? Given that point certainty, what wiggle room do you have with either the top or the low end of that guide? Second, please, Martin, you mentioned ACA subsidies expiring. How have you or will you account for patients that have signed up to ACA marketplaces in January, but have missed the one, three-month grace period for their first payment? I guess, in other words, would there be a stronger impact in Q2 from your EUR 50 million headwinds or some type of reversal that we think about? Thank you. Martin, do you want to take the inflation question? Thank you, Hugo. So far for the first quarter, we are tracking in line with our assumptions on the inflation side. We also saw only minimal impact from the conflict and from the macro environment. We are closely monitoring that, as Helen outlined, and we are also taking mitigating actions. For quarter one, this is well in line with the development. As we see it, as of today, this is also something that is within the band of our assumptions for inflation as well. Yeah. Then maybe on the ACA subsidies, you know that we had guided, you know, this impact of around EUR 50 million. Obviously, what we, you know, we're watching closely is what happened through open enrollment, what, you know, the uptake of patients or where patients are getting their insurance coverage. Since the open enrollment closed, we always said it would take Q1 to play out to see how that was. What we've actually seen in Q1 is maybe lower than planned or lower than thought patient attrition. Some of that, you know, the mechanics of how it worked was they're auto-enrolled, they've got then they had to make their first payment for their first, you know, month of coverage. We don't know after that first month whether they stayed on or didn't. There is this grace period that is happening. We don't know, you know, from an affordability standpoint whether they will stay on, you know, on an exchange and, or move to, you know, Medicare, you know, or Medicare Advantage after that. We're roughly at the point where they should be making their first premium, and I think that's a real test, you know, kind of test point for us. While we didn't see much impact in Q1, our expectation is affordability will become an issue. Right now, we believe our assumption for EUR 50 million for the year is still a good estimate, but we would not necessarily start to see that impact until Q2, and obviously then compounded Q3, Q4. It's something we're watching closely, but holding the assumption for now. Good. Okay. Thank you. The next question comes from Aisyah from Morgan Stanley. Aisyah, the floor is yours. Hi, everyone. Thanks for taking my question. My first one is hopefully a quick one on China. Could you quantify the impact from VBP and the tender exclusion in the quarter versus the guidance of, I think, EUR 50 million or a bit less than EUR 50 million that you saw last year? Do you have a clearer view on when you could reenter the tender this year? The second question, also hopefully quick, is on Value-Based Care. Your performance in the quarter was clearly ahead of your expectations of a decline for the full year. Would this mean that we just see a steeper decline for the remainder of the year, or does this drive a bit of upside to the original guidance? At what point do you think you'll have better visibility on the margin side of things? Thank you. Yeah. Martin, do you wanna take those two financial questions? Yes, more than happy to. Aisyah, on China, yes, we gave a expectation that we would see a little bit of below EUR 50 million for the full year. We did see also in quarter one about half of that come through as we expected, and this is in line with how we looked at China for the full year. Obviously also then we do see lower effects in the coming quarters to that extent. When we talk about Value-Based Care, yes, you are right. We had a bit of a uptick in the quarter where we had a mix of revenues being driven also by prior period adjustments, which is helping us to offset the headwinds that we have from the revenue recognition of a differently casted contract. I think it is too early, given the volatility, of the Value-Based Care business, quarter one being a, let's say proof point, so to say, in the positive, to change the outlook for the year. We have given you a EUR 300 million assumption, and that is still what we're going to work with. Thank you. If, Martin, if I could push a little bit as well on the inflation side, which you talked a bit earlier. You mentioned you're monitoring the situation closely, but to the extent that the current conflict is prolonged, which areas of your cost base would you see most sensitive to incrementally higher inflation as a result? Would it be energy, freight, plastics, et cetera? Appreciate you're not seeing any impact at the moment. Yeah. You know, in a worst case scenario. When we look at different buckets, typically you look at energy, you look at transportation costs, everything that's exposed to oil price, also on the oil price-based materials like plastics and stuff like that. On the energy side, we are rather well hedged, so 70% of our exposure is hedged, so I would call that a limited exposure. Having said that, when there would be a continued high oil price dependency, obviously transportation like with everybody else or plastic-based oil dependencies would see a potential inflation and cost increase if this is very much prolonged. Okay. Thank you. Also, as I said, perhaps one last thing here. We are currently, and that's what I answered Hugo in his question, absorbing that in our guidance assumption for the year. Okay. Good. Thank you. The next question comes from Anna from Bank of America. Anna, the floor is yours. Hi. Thank you for taking the question. I wanted to follow up on what Veronika was asking about the HVHDF rollout, and how the costs are unfolding versus your expectations. I think you said you rolled out 200 clinics versus an implied goal of closer to 500. Should we be thinking that the costs accelerate in Q2, and into the back half of the year, maybe compounding the headwind from the TDAPA roll-off? I don't wanna get ahead of myself, but how are you thinking about that going into 2027, the cost for the ongoing rollout there? I think previously you'd messaged that the savings from the HVHDF rollout would offset the cost. Is that still the right way to think about it, or maybe will it be more of a similar magnitude? Thank you for taking the questions. Yeah. Anna, our plan is obviously to, you know, kind of replace about 20% of the machines, of the installed base in 2026. As you can appreciate, you know, the costs are front-end loaded because we have to train. We train, we get installed, we run, and then obviously the benefits lag. As you can appreciate, the costs will continue to accelerate as we continue to accelerate the clinic closure. You know, it's more just in, you know, kind of linear to the number of machines that we install over the course of the year. You know, I think that, you know, the piece that you're maybe trying to tease out is we have costs and then the benefits lag, but there'll come a point where the benefits will be absorbing some of those costs in the later years. It's, you know, that lag kind of sorts itself out on an annualized basis. Nothing I don't think anything remarkable to comment on the costs outside of, you know, what we had originally guided, and now it's in line with the number of machines that we deploy. Okay, good. Thank you. The next question comes from Oliver from ODDO. Oliver, the floor is yours. Yeah, good afternoon. Thanks for taking my questions. The first one is on the payer mix. Over the last quarters, we have seen or you have reported some progress. This was also again confirmed now. Up from now, how you think about further improvements in the payer mix. Is it still some source for additional profitability or at one point of time, it's basically it's becoming more neutral? The second question is about Value-Based Care. In your report has also shown a solid increase, I think 5% of enrollment of new patients. Can you provide some data whether the growth now comes more from CKCC or from commercial programs, and how do you think about further patient growth in VBC? Thank you. I think I can take both of those. You know, in the payer mix improvement, we are very pleased with how we continue to improve that mix. Obviously, that right now there's no ACA headwind in that because we're still holding on to those patients. There is an expectation, you know, that, you know, depending on what happens with ACA, that might, that might change. The other thing I would say is clearly we are focused on improving that weight and the focus on profitable growth. As we, you know, close clinics, you know, we don't hold on to 100% of the patients. We know that. Obviously the focus here is on, you know, the kind of the profitable mix there. I think also, you know, the opportunity to be talking to payers as well about some of these new initiatives that, you know, that we're focused on, notwithstanding HDF and some of the other pieces. We are, we are pleased with how that is developing and the, and the conversations there and continues to, you know, slightly tick up each quarter. On VBC, obviously in the quarter, you know, Martin spoke to this already, there was a prior year true up. I would say, you know, we are, you know, we've got a new leader now. We're kind of got a really good strategic focus here on finding the growth in both the contracts and, you know, better contracting and premiums, as well as member months. I would say that improvement is coming more from commercial than it is from CKCC. Obviously, we are really focused on improving the contract status that we have there and have had some nice wins and some nice discussions, and new relationships with some of the larger payers. Okay. Thank you. Of course. The next question comes from James from Jefferies. James, the floor is yours. Hi. Thanks for taking my question. Just a couple, please. Firstly, on operating cash flow. Notice it's EUR 227 million in the quarter, up 40%. I guess there's a summary on slide 12, but just wondering what goes into the other working capital and non-cash items. That was a positive inflow of EUR 133 million or nearly 60% of the operating cash flow. Because if you wanna adjust for that line, I appreciate there might be some other stuff that goes in there. It implies a 50% reduction in operating cash flow. I just wonder if you can give some color, what goes into that line, and also just confirm if there's any factoring. My second question is, full year, there was the slide on the outlook assumptions. Just because that was missing in the deck this time, can you confirm that all of those are still valid? Thanks very much. Okay, James. Why don't I take the full year outlook assumptions while I let Martin maybe have a look at the cash flow question, and we may have to follow back up on that. Yeah, look, we don't include that headwinds and tailwinds slide every quarter. We generally talk about it in full year about what we're mapping, and then maybe half year or speak to any major variations. You know, I would say, you know, as we look at that internally, that classification, that is really developing in line with expectations. Nothing significant to point out there. The, you know, the headwinds and tailwinds are very much, you know, from what we've seen in Q1 and our outlook for the year, are developing in line with as we expected. Okay. Perhaps, what I can say, and then might have to come back to you, James, is we are driving operating working capital improvements for the underlying the cash performance. On that other piece that you refer to, I would have to understand exactly what you refer to and come back. Okay. Thank you. you. The next question comes from David from JP Morgan. David, the floor is yours. Hey, guys. Thanks for the question. Sorry to re-bang on the drum of both ACA and cost inflation. Maybe first on ACA, I just wanted to double-check. Have you recognized all the revenues from patients coming through? If they fall off, sort of going forward from here, will you have to go back and readjust numbers or take a revision, or have you made some sort of provision through the first quarter just in case those guys do come off, you might be able to write it back later if they don't? The second question is on cost inflation, maybe for Martin. I just wonder what percentage of your costs in Care Enablement is particularly associated with plastics and actually what you're seeing in terms of plastics inflation there? Thank you. David, on the ACA question, obviously, we have a patient, we would be billing for that treatment for that patient. There's no kind of It's just particularly it's billed. I think our concern is more if they fall off insurance or they go out of the system that we lose that patient and obviously that revenue that comes from that. I think that's why we can say there's not really an impact in Q1 because our patient census didn't have the attrition that we first thought. you know, obviously we're also looking pretty hard at the front-end process on insurance verification and things like that. There shouldn't be an impact. We just take it, you know, as the patient is there and then doing the insurance verification to make sure, you know, we're billing accordingly. I think that's why we're saying we'll hold the assumption because we don't know if these patients will fall off, once they make their first premium payment in Q2, Q3, or rest of the year. They do have to be covered. If they're on, they will get covered by the, by the insurance company in what we call this grace period, but it's after that is the risk for the patient coming off the exchange. That's clear. Martin, regarding inflation? Yes. Yeah. Okay. David, regarding the inflation question, as I said, we are monitoring the situation closely. There is multiple buckets where, oil dependency impacting transportation cost is one, plastics are another one. I don't want to give you a number of our costs, because we have a supply chain that has different exposures. Obviously, we are manufacturing also our plastics parts like the bloodlines or like also other consumables in different locations. As such, it is not a simple extrapolation. We are working on this. We are mitigating the effect. We have it inside our inflation guidance that we gave for the market, and I think that is, from my or from our perspective, the right way to look at it. Fair enough. Thanks so much. Yep. Thank you. The next question comes from Falko, from Deutsche Bank. Falko, the floor is yours. Thank you. Good afternoon. Two questions, please. The first one, can you remind us how much of your Care Enablement sales are coming from China? How was growth excluding China in the first quarter for the segment? Secondly, on Care Delivery, the organic growth in the international business was a tad softer than in previous quarters. Was there any particular reason for that, or was that just normal quarterly volatility? Thank you. Wanna take this? On the yeah, on the China one, Falko, we said it's about 7% - 10% of the revenues that we have in Care Enablement. It is a relevant market, it's also an attractive market. We have not disclosed for the quarter what the top-line impact is overall. Yeah. Your question on CDI. As you know, we're kind of continuing to refine that portfolio, on, you know, kind of where that treatment growth is coming. It does look a little bit lower, don't forget, last year we had Brazil in the base. As we look at this market by market, we're, you know, not concerned with what we're seeing. I think it's just maybe a tough comp because of Brazil. Okay. Thank you. Thank you. The last question comes from Richard from Goldman Sachs. Richard, the floor is yours. Great. Thank you very much for squeezing me in. Just a follow-up on China for Care Enablement. Between the stricter tender requirements and VBP, how are you seeing competitive dynamics in that market change, if at all? Martin, you just referenced China as being an attractive market. What kind of scenario is embedded in your medium-term plans for Care Enablement in China, please? Thank you. Yeah. Richard, look, China is an attractive market for us. It's a large market. The profitability is there despite some of the, you know, the challenges that we have, you know, we've already experienced. I think we're eyes wide open of what it takes to succeed in China. Obviously, there, we're hearing this across med tech, the competitive dynamics are changing. I think for us it's about having the right strategy and the right go-to-market approach in China and the right portfolio of what is local for local and what is really premium. You know, we have some good assumptions into our mid, you know, mid-range plans. We are obviously getting under the current environment and what the future portfolio should look like for China. Obviously, if these, if these dynamics continue to evolve, we will strategically adjust accordingly on the portfolio. We know we were, you know, we were later into China than some med tech companies, so we learned a lot. Even with that, we obviously had some impact. You saw that, you know, hit us last year. You know, a lot of the focus is on what is the right portfolio to have in China for the China market, what can we do local, what can we partner. You know, I think then we have to look at China in relation to the global portfolio that we're developing and see what it is that we need to have offered there for continued success. I'm, I think just more to come here, as we continue to look at that strategy and the portfolio in light of these changing regulations that, you know, are happening in real time. Thank you very much. Bye. Thank you. With that, we have answered all questions. The time is up, so perfect combination. With that, thank you for being so interested, that we filled more than an hour. With that, we'll say thank you, see you on the road, on conferences and around the world. Thanks, everybody. Thank you. Have a good day. Bye-bye. Bye. Bye-bye. Ladies and gentlemen, the conference is now over. Thank you for choosing Chorus Call, and thank you for participating in the conference. You may now disconnect your lines. Goodbye.